adjuvin 50mg potahovaná tableta
g.l. pharma gmbh, lannach array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
setaloft 50mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
stimuloton 50mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
metoprolol aurovitas 100mg potahovaná tableta
aurovitas, spol. s r.o., praha array - 4634 metoprolol-tartarÁt - potahovaná tableta - 100mg - metoprolol
metoprolol medreg 100mg potahovaná tableta
medreg s.r.o., praha array - 4634 metoprolol-tartarÁt - potahovaná tableta - 100mg - metoprolol
zoloft 50mg potahovaná tableta
upjohn eesv, capelle aan den ijssel array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
frimig 100mg potahovaná tableta
orion corporation, espoo array - 10645 sumatriptan-sukcinÁt - potahovaná tableta - 100mg - sumatriptan
sertraline hydrochloride- sertraline hydrochloride tablet, film coated
remedyrepack inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline hydrochloride tablets are indicated for the treatment of the following [see clinical studies (14)] : - major depressive disorder (mdd) - obsessive-compulsive disorder (ocd) - panic disorder (pd) - posttraumatic stress disorder (ptsd) - social anxiety disorder (sad) - premenstrual dysphoric disorder (pmdd) sertraline hydrochloride tablets are contraindicated in patients: - taking, or within 14 days of stopping, maois, (including the maois linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)] . - taking pimozide [see drug interactions (7.1)] . - with known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [see adverse reactions (6.1, 6.2)]. risk summary overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in compar
sertraline hydrochloride solution, concentrate sertraline hydrochloride tablet, film coated
greenstone llc - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline hydrochloride is indicated for the treatment of the following [see clinical studies (14)] : sertraline hydrochloride is contraindicated in patients: in addition to the contraindications for all sertraline hydrochloride formulations listed above, sertraline hydrochloride oral solution is contraindicated in patients: risk summary overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in comparator populations. some studies have reported increases for specific major birth defects; however, these study results are inconclusive [see data] . there are clinical considerations regarding neonates exposed to ssris and snris, including sertraline hydrochloride, during the third trimester of pregnancy [see clinical considerations]. although no teratogenicity was observed in animal reproduction studies, delayed fetal ossification was observed when se
sertraline- sertraline hydrochloride tablet, film coated
hikma pharmaceuticals usa inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline tablets, usp are indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the antidepressant action of sertraline in hospitalized depressed patients has not been adequately st